UT-MD Anderson Cancer Center: SABCS - Studies Suggest Novel Targeted Therapies May Benefit Patients With Metastatic HR+/ HER2- Breast Cancer
December 07, 2023
December 07, 2023
HOUSTON, Texas, Dec. 7 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson-led trials demonstrate clinical benefit from futibatinib, tinengotinib in most common breast cancer subtype
* * *
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patient . . .
* * *
MD Anderson-led trials demonstrate clinical benefit from futibatinib, tinengotinib in most common breast cancer subtype
* * *
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patient . . .